Active, not recruiting
An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma
NCT02648997
- Conditions
- Central Nervous System Neoplasms, Meningeal Neoplasms, Meningioma, +8 more
- Locations
-
- Dana-Farber Cancer Institute Boston, Massachusetts, United States